U.S. markets open in 25 minutes
  • S&P Futures

    3,699.50
    -9.50 (-0.26%)
     
  • Dow Futures

    29,606.00
    -63.00 (-0.21%)
     
  • Nasdaq Futures

    11,373.75
    -3.00 (-0.03%)
     
  • Russell 2000 Futures

    1,680.60
    -5.50 (-0.33%)
     
  • Crude Oil

    79.09
    +0.35 (+0.44%)
     
  • Gold

    1,653.80
    -1.80 (-0.11%)
     
  • Silver

    18.86
    -0.05 (-0.26%)
     
  • EUR/USD

    0.9673
    -0.0015 (-0.15%)
     
  • 10-Yr Bond

    3.7610
    +0.0640 (+1.73%)
     
  • Vix

    31.78
    +4.43 (+16.20%)
     
  • GBP/USD

    1.0866
    +0.0009 (+0.08%)
     
  • USD/JPY

    143.9460
    +0.6260 (+0.44%)
     
  • BTC-USD

    19,087.58
    +4.12 (+0.02%)
     
  • CMC Crypto 200

    437.43
    -7.10 (-1.60%)
     
  • FTSE 100

    6,966.04
    -52.56 (-0.75%)
     
  • Nikkei 225

    26,431.55
    -722.28 (-2.66%)
     

Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform

·1 min read
  • Low profile startup Rona Therapeutics Inc has obtained exclusive rights worldwide to Sanofi SA's (NASDAQ: SNY) siRNA platform of chemical modification and delivery moiety.

  • Rona Therapeutics will make an upfront payment to Sanofi, in addition to development and commercial milestones, as well as royalties on net sales of products.

  • Deal terms were not disclosed.

  • These rights will enable Rona to expand and accelerate its siRNA portfolio in liver and non-liver applications.

  • Sanofi receives an exclusive option for selected neuro, and muscular candidates discovered using the siRNA platform for territories outside mainland China, Hong Kong, Taiwan, and Macao.

  • Under the deal, Rona also acquired rights to develop, manufacture, and commercialize candidates from four liver-targeting preclinical programs.

  • "Rona plans to quickly advance the development of these programs in metabolic, neurological, and ocular diseases to unlock the potential of siRNA therapeutics," said Stella Shi, CEO of Rona Therapeutics.

  • Sanofi had initially announced an RNA partnership with Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) for hemophilia treatment.

  • Safety issues forced a revamp of that late-stage program when Sanofi flagged a failure for its microRNA drug lademirsen, partnered with Regulus Therapeutics Inc (NASDAQ: RGLS).

  • The companies teamed up back in 2010, signing a deal worth $25 million upfront and up to $750 million in milestones.

  • Price Action: SNY shares are up 0.76% at $50.21 during the market session on the last check Monday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.